⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte presenterà gli ultimi dati sull'idrosadenite suppurativa (HS) al Meeting annuale 2026 della American Academy of Dermatology (AAD)
businesswire.com
INCY
Incyte presentará los últimos datos sobre la hidradenitis supurativa en el Congreso Anual de la Academia Estadounidense de Dermatología (AAD) de este año
businesswire.com
INCY
Incyte presentará los últimos datos sobre la hidradenitis supurativa en el Congreso Anual de la Academia Estadounidense de Dermatología (AAD) de este año
businesswire.com
INCY
Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen
businesswire.com
INCY
Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen
businesswire.com
INCY
Incyte présentera des données de dernière minute sur l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD)
businesswire.com
INCY
Samenvatting: Incyte belicht meest recente gegevens met betrekking tot hidradenitis suppurativa tijdens de 2026 AAS (American Academy of Dermatology) Annual Meeting
businesswire.com
INCY
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
businesswire.com
INCY
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
globenewswire.com
INCY
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
globenewswire.com
INCY